



AGENDA: DUR BOARD MEETING

**Health First Colorado, Colorado Medicaid, Drug Utilization Review Board
Department of Health Care Policy and Financing**

This will be a virtual attendance-only meeting

Virtual meeting details will be posted prior to the meeting on the DUR webpage at <https://www.colorado.gov/pacific/hcpf/drug-utilization-review-board> .

May 12th, 2020

**5:00 p.m. – 9:00 p.m. Open Session (Note change in starting time!)
DUR BOARD MEMBERS and CO-DUR MEMBERS**

DUR Board Members	CO-DUR Team
Michael Noonan, DO (Chair) Gosia Thomas, PharmD (Vice-Chair) Allison Blackmer, PharmD Alison Shmerling, MD (New members and re-applying members are pending HCPF approval)	Jeffrey Taylor, PharmD (HCPF) Robert L Page, PharmD, MSPH (CO DUR) Brandon Utter, PharmD (CO DUR) Heather Anderson, PhD (CO DUR) Garth Wright, MPH (CO DUR) Gina Moore, PharmD, MBA (CO DUR)

Announcing New Chair/Vice Chair

Roll Call / Introductions and welcome to new members

Approval of Minutes from February 11th, 2020 Meeting

Reading of Rules for Public Testimony and Disclosure of Conflicts of Interest:

- Agenda items must be approved in advance, including requests to present information. Please contact the DUR Pharmacist, Jeff Taylor, at jeffrey.taylor@state.co.us with questions.
- Anyone wishing to provide testimony must contact the DUR Pharmacist at least 24 hours before the meeting.

Open Session:

Unfinished Business and General Orders:

- Colorado Department of Health Care Policy and Financing Updates
- Retrospective DUR Updates





COLORADO

Department of Health Care Policy & Financing

- Quarterly Module Summary
- FDA Updates
- Quarterly Drug Utilization Reports

Updates on Business from Last Meeting:

(items included in this section are not scheduled for public testimony or board review as part of this agenda)

- Antimigraine Agents – Calcitonin Gene-Related Peptide (CGRP) Inhibitors
- Diabetes Management – Insulins
- Glucagon, Self-Administered
- Multiple Sclerosis Agents
- Immune Globulins
- Anti-Parkinson's Agents
 - Dopa Decarboxylase Inhibitors & Combinations
 - MAO-Bs
 - Dopamine Agonists
 - Other
- Atypical Antipsychotics
- Lithium Agents
- Ophthalmic Anti-Inflammatories
- Lipotropics
- Sedative Hypnotics
 - Non-Benzodiazepine
 - Benzodiazepine
- Hemorrhoidal and Related Anorectal Agents
- Growth Hormones
- **Mass review drug classes:**
 - Bile Salts
 - Growth Hormones
 - Intranasal Rhinitis Agents
 - Leukotriene Modifiers
 - Neurocognitive Disorder Agents
 - Ophthalmic Allergy Agents
 - Ophthalmic Glaucoma Agents
 - Statins & Statin Combinations
 - Topical Steroids
 - Low Potency
 - Medium Potency
 - High Potency
 - Very High Potency
- Trikafta (elexacaftor, tezacaftor, and ivacaftor)
- Exondys 51 (eteplirsen injection)
- Vyondys 53 (golodirsen)

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.
www.colorado.gov/hcpf





COLORADO

Department of Health Care
Policy & Financing

New Business (open for public testimony and board review):

Proposed Criteria for PDL Drug Classes Scheduled for Review:

- Non-Opioid Analgesics
- Opioids –Long-Acting
- Opioids –Short-Acting
- Tetracyclines
- Angiotensin Modulators and Angiotensin Modulator Combinations
 - ACE Inhibitors, ACE Inhibitor Combinations
 - ARBs, ARB Combinations
 - Renin Inhibitors & Combinations
- Acne Agents
 - Topicals
 - Oral Isotretinoins
- Androgenic Agents
 - Topicals
 - Injectables
 - Orals
- Respiratory Inhalants
 - Inhaled Anticholinergics & Anticholinergic Combinations
 - Inhaled Beta2Agonists (short-acting)
 - Inhaled Beta2Agonists (long-acting)
 - Inhaled Corticosteroids and Combinations
- **Mass review drug classes*:**
 - Skeletal Muscle Relaxants
 - Rosacea Agents, Topical
 - Antihistamines, Newer Generation & Combinations
 - Topical Immunomodulators
 - Phosphate Binders
 - Benign Prostatic Hypertrophy (BPH) Agents

Proposed ProDUR and Prior Authorization Criteria for Other Selected Products:

- Nayzilam (midazolam)
- Valtoco (diazepam)
- Dupixent (dupilumab)
- Soliris (eculizumab)
- Ergomar (ergotamine)
- Migergot (ergotamine)
- Thiola EC (tiopronin)
- Review of Products for Proposed Drug Label Prior Authorization:
 - Ultomiris (ravulizumab)
 - Revcovi (elapegademase-lvlr)
 - Lumizyme (alglucosidase alfa)
 - Adakveo (crizanlizumab-tmca)

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.
www.colorado.gov/hcpf





COLORADO

**Department of Health Care
Policy & Financing**

- Pretomanid

**Proposed criteria for drug classes designated for mass review will not be read aloud at the time of DUR Board review, as there are no proposed changes to criteria previously implemented for these designated classes. The DUR Board may determine if designated mass review drug classes will undergo full review based on board vote.*

Adjourn

Reasonable accommodations will be provided upon request for persons with disabilities. Please notify the Board Coordinator at 303- 866-3105 or jeffrey.taylor@state.co.us or the 504/ADA Coordinator hcpf504ada@state.co.us at least one week prior to the meeting to make arrangements.

